982 California job cuts precede Actavis, Allergan merger
This article was originally published in Scrip
Executive Summary
Before the quickly negotiated $66bn acquisition of Allergan by Actavis to thwart an unwanted deal proposed by Valeant Pharmaceuticals, Allergan began executing its well-known plan to cut jobs in California and Actavis had its own layoffs under way in the Golden State.
You may also be interested in...
Allergan Readies Cost Cuts As Restasis Generics Approach
Allergan is working on a plan to reduce costs now that Restasis generics could hit the US market in 2018, but the company said sales growth for other drugs coupled with new product launches will boost revenue even if the dry eye drug loses its blockbuster status.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.